Form 4: MaxCyte Director John Johnston Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Director John Johnston exercised stock options and sold shares of MaxCyte, Inc. (MXCT) on August 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On August 26, 2024, John Johnston, a director of MaxCyte, Inc. (MXCT), exercised stock options to acquire 3,000 shares of common stock at a price of $2.926 per share.
- Simultaneously, Johnston sold 3,000 shares of MaxCyte common stock at a weighted average price of $4.28, with individual sales ranging from $4.23 to $4.35.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on December 19, 2023.
- Following these transactions, Johnston directly owns 141,950 shares of MaxCyte common stock and 7,396 stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reflects routine insider trading activity under a pre-arranged plan. There's no indication of positive or negative implications for the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It's common for corporate insiders to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of trading on non-public information. The market will likely interpret this as a routine transaction.
Key Dates
| Date | Description |
|---|---|
| 2023-12-19 | Date of adoption of Rule 10b5-1 trading plan. |
| 2024-08-26 | Date of stock option exercise and share sale. |
| 2024-08-28 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.